Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor

Thrombosis and Haemostasis
Meyer Michel SamamaElisabeth Perzborn

Abstract

Although there is no need for routine coagulation monitoring with rivaroxaban--an oral, direct factor Xa inhibitor--a haemostasis assay might be valuable to measure its pharmacodynamic effects. This study aimed to find assays, among those commercially available, to measure rivaroxaban pharmacodynamics. Several global conventional clotting tests, as well as clotting or chromogenic assays to measure anti-factor Xa activity, were studied. A thrombin generation test using calibrated automated thrombogram was also done. Tests were performed with the indirect factor Xa inhibitor fondaparinux for comparison. A concentration-dependent prolongation of prothrombin time (PT), dilute PT, and activated partial thromboplastin time was observed with rivaroxaban. The results varied depending on the reagents. This variability cannot be standardised with the international normalised ratio system commonly used for vitamin K antagonists. Using a standard calibration curve, PT test results can be expressed in plasma concentrations of rivaroxaban rather than PT seconds or ratio. Standard methods for HepTest and two-step prothrombinase-induced clotting time (PiCT) resulted in a paradoxical response, with low concentrations of rivaroxaban reducing clo...Continue Reading

Citations

Nov 12, 2010·Der Unfallchirurg·S SiebenlistU Stöckle
Mar 16, 2011·Wiener medizinische Wochenschrift·Charles Marc Samama
Aug 9, 2011·Pharmaceutical Research·Abhishek GulatiStephen B Duffull
Oct 20, 2009·Journal of Thrombosis and Thrombolysis·Meyer Michel Samama, Grigoris T Gerotziafas
Feb 6, 2013·Journal of Thrombosis and Thrombolysis·Barbara A Konkle
Feb 8, 2013·Journal of Thrombosis and Thrombolysis·Deborah M Siegal, Adam Cuker
Mar 21, 2013·Journal of Thrombosis and Thrombolysis·Helen ManiEdelgard Lindhoff-Last
May 8, 2013·Current Rheumatology Reports·Deepa Jayakody Arachchillage, Hannah Cohen
Sep 3, 2013·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·M B AgarwalS Bichu
Aug 21, 2013·Best Practice & Research. Clinical Haematology·Raji Shameem, Jack Ansell
Sep 24, 2013·The Veterinary Journal·Bérénice ConversyJérôme R E del Castillo
May 22, 2013·Nature Reviews. Cardiology·John N MakaryusJoe F Lau
Dec 15, 2010·British Journal of Anaesthesia·J J van VeenM Makris
Dec 12, 2012·European Heart Journal·Deborah M Siegal, Mark A Crowther
Jun 10, 2011·Thrombosis and Haemostasis·Helen ManiEdelgard Lindhoff-Last
Jun 15, 2013·Thrombosis and Haemostasis·Jonathan DouxfilsFrançois Mullier
Oct 25, 2012·Biochemia Medica·Emmanuel J Favaloro, Giuseppe Lippi
Jun 29, 2013·Critical Care : the Official Journal of the Critical Care Forum·Alejandro Lazo-LangnerJames Douketis
Nov 30, 2011·PloS One·Thomas OrfeoKenneth G Mann
Feb 4, 2011·Clinical Chemistry and Laboratory Medicine : CCLM·Meyer M Samama, Céline Guinet
Jul 11, 2012·Hämostaseologie·T HelbingM Moser
Nov 23, 2010·Journal of Atherosclerosis and Thrombosis·Selvakumar Velu, Gregory Y H Lip
Sep 4, 2013·Clinical Pharmacokinetics·Wolfgang MueckMichael Becka
Nov 5, 2013·Future Cardiology·Carrie S OliphantPranab Das
Jun 28, 2014·Critical Care : the Official Journal of the Critical Care Forum·Bappaditya Ray, Salah G Keyrouz
Aug 9, 2011·Annales Françaises D'anesthèsie Et De Rèanimation·P SiéP Albaladejo
Aug 30, 2014·Clinics in Laboratory Medicine·Meyer Michel SamamaCharles Marc Samama

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.